NasdaqCM:CPRXBiotechs
How Expanded NCCN Guidelines for FIRDAPSE Have Changed the Investment Story at Catalyst Pharmaceuticals (CPRX)
Earlier this month, Catalyst Pharmaceuticals reported strong second quarter results, reaffirmed its full-year 2025 revenue guidance of US$545 million to US$565 million, and highlighted that new NCCN guidelines now include its lead product, FIRDAPSE, for Lambert Eaton myasthenic syndrome associated with small cell lung cancer.
This guideline update may significantly expand the recognized patient population for FIRDAPSE, potentially increasing diagnosis rates and strengthening Catalyst’s...